“We all need an understanding of patient advocacy group capabilities – we need to be real about our own capabilities too.” Jeanne Regnante, Executive Director, Head, Patient engagement strategy office, Office of the CPO, Merck & Co
Although patient advocacy and pharma have different starting points, they still share the common goal – to improve lives of people suffering from a particular condition. Despite this, many in pharma struggle to collaborate with these groups in a meaningful way.
That is why MK&A and eyeforpharma asked a range of global patient advocacy groups about their engagement with industry, academia, and the regulators to date and compiled it in our latest whitepaper: “Incorporating the Patient’s Voice: Analysis of The Global Patient Advocate Survey”
Fill in the form on the right to download the full survey results and analysis >>
This exclusive 22-page whitepaper also compiles expert commentary from the following leaders, on how to successfully engage with patient advocacy groups: